He Fang, Matsumoto Yoshinori, Asano Yosuke, Yamamura Yuriko, Katsuyama Takayuki, La Rose Jose, Tomonobu Nahoko, Komalasari Ni Luh Gede Yoni, Sakaguchi Masakiyo, Rottapel Robert, Wada Jun
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada.
Front Oncol. 2021 May 31;11:665273. doi: 10.3389/fonc.2021.665273. eCollection 2021.
Activity of transcription factors is normally regulated through interaction with other transcription factors, chromatin remodeling proteins and transcriptional co-activators. In distinction to these well-established transcriptional controls of gene expression, we have uncovered a unique activation model of transcription factors between tyrosine kinase ABL and RUNX2, an osteoblastic master transcription factor, for cancer invasion. We show that ABL directly binds to, phosphorylates, and activates RUNX2 through its SH2 domain in a kinase activity-dependent manner and that the complex formation of these proteins is required for expression of its target gene MMP13. Additionally, we show that the RUNX2 transcriptional activity is dependent on the number of its tyrosine residues that are phosphorylated by ABL. In addition to regulation of RUNX2 activity, we show that ABL transcriptionally enhances RUNX2 expression through activation of the bone morphogenetic protein (BMP)-SMAD pathway. Lastly, we show that ABL expression in highly metastatic breast cancer MDA-MB231 cells is associated with their invasive capacity and that ABL-mediated invasion is abolished by depletion of endogenous RUNX2 or MMP13. Our genetic and biochemical evidence obtained in this study contributes to a mechanistic insight linking ABL-mediated phosphorylation and activation of RUNX2 to induction of MMP13, which underlies a fundamental invasive capacity in cancer and is different from the previously described model of transcriptional activation.
转录因子的活性通常通过与其他转录因子、染色质重塑蛋白和转录共激活因子相互作用来调节。与这些已确立的基因表达转录调控不同,我们发现了酪氨酸激酶ABL与成骨细胞主转录因子RUNX2之间一种独特的转录因子激活模型,该模型与癌症侵袭有关。我们发现,ABL通过其SH2结构域以激酶活性依赖的方式直接结合、磷酸化并激活RUNX2,并且这些蛋白的复合物形成是其靶基因MMP13表达所必需的。此外,我们发现RUNX2的转录活性取决于被ABL磷酸化的酪氨酸残基数量。除了对RUNX2活性的调节,我们还发现ABL通过激活骨形态发生蛋白(BMP)-SMAD途径转录增强RUNX2的表达。最后,我们发现高转移性乳腺癌MDA-MB231细胞中ABL的表达与其侵袭能力相关,并且内源性RUNX2或MMP13的缺失可消除ABL介导的侵袭。我们在本研究中获得的遗传和生化证据有助于深入了解ABL介导的RUNX2磷酸化和激活与MMP13诱导之间的机制联系,这构成了癌症基本侵袭能力的基础,并且不同于先前描述的转录激活模型。